The Alzheimer’s Laboratory
Eli Lilly’s Experimental Alzheimer’s Drug Fails in Large Trial
An experimental Alzheimer’s drug that had previously appeared to show promise in slowing the deterioration of thinking and memory has failed in a large Eli Lilly clinical trial, dealing a significant disappointment to patients hoping for a treatment that would alleviate their symptoms.
Dominantly Inherited Alzheimer Network Trial (DIAN-TU-001) continues despite results from Eli Lilly and Company’s EXPEDITION3 trial
German Families with Dominantly Inherited Alzheimer’s Disease Meet for the First Time
Nobody knew each other’s name. Even so, 60 people who either were at risk of having an autosomal-dominant Alzheimer’s mutation, or were accompanying someone who was, exchanged information about a shared problem. There were moments of validation—“Denial has divided my family, too!”—and apprehensive questions—“Do you want to know if you have it?”
Why Most Alzheimer’s Research Is Done On Early-Onset Patients Like Pat Summitt
Family places hope in drug trial for hereditary Alzheimer’s gene mutation
Alzheimer’s Disease: Daisy’s Story
Man looking for answers with new Alzheimer’s study
He has the disease and he’s lost five family members to it, now he’s enrolled in a study hoping to find some answers in Alzheimer’s disease.
Trial aims to prevent Alzheimer’s in those genetically predisposed
A first-of-its-kind study is testing the use of antibody drugs to prevent or slow down the onset of Alzheimer’s disease in individuals genetically destined to develop the illness at an early age.